Does Aetna Cover Eliquis?

What Is Eliquis and Why Coverage Matters

Eliquis (apixaban) is a direct oral anticoagulant (DOAC) that works by selectively inhibiting Factor Xa, interrupting the coagulation cascade before thrombin generation. The FDA approved apixaban in December 2012 for stroke and systemic embolism prevention in nonvalvular atrial fibrillation, and later expanded that label to include treatment and secondary prevention of deep vein thrombosis (DVT) and pulmonary embolism (PE), as well as prophylaxis after hip or knee replacement surgery. FDA label for Eliquis

Atrial fibrillation (AF) affects an estimated 2.7 million to 6.1 million Americans, according to the CDC, and that number is projected to reach 12.1 million by 2030. CDC AF fact sheet For most of these patients, long-term anticoagulation is not optional. It is the standard of care under ACC/AHA guidelines, which recommend DOAC therapy over warfarin for most patients with nonvalvular AF and a CHA₂DS₂-VASc score of 2 or higher in males and 3 or higher in females. The cost of Eliquis therefore has direct clinical consequences. Patients who cannot afford their prescription may stop taking it, raising their stroke risk significantly.

The ARISTOTLE trial (N=18,201) compared apixaban 5 mg twice daily to warfarin in patients with AF. Apixaban reduced the rate of stroke or systemic embolism by 21% (1.27% per year vs. 1.60% per year, hazard ratio 0.79 to 95% CI 0.66 to 0.95, P<0.001 for non-inferiority and P=0.01 for superiority). Major bleeding occurred at a rate of 2.13% per year with apixaban versus 3.09% with warfarin (hazard ratio 0.69, P<0.001). ARISTOTLE trial, NEJM 2011 Those efficacy and safety margins explain why cardiologists and hematologists prescribe Eliquis heavily, and why coverage disputes carry real clinical weight.

How Aetna Formularies Are Organized

Aetna uses a tiered formulary system in which each drug is assigned to a cost-sharing tier. Understanding where Eliquis falls requires knowing which specific Aetna product a patient is enrolled in, because Aetna administers dozens of distinct plan types: commercial PPO and HMO plans, Medicare Advantage (MA) plans with integrated Part D drug coverage, standalone Medicare Part D Prescription Drug Plans (PDPs) administered through SilverScript (an Aetna subsidiary), Medicaid managed care contracts in certain states, and student health plans.

Tier definitions vary somewhat across plan documents, but a general framework looks like this:

• Tier 1: Preferred generics, typically $0, $15 per month
• Tier 2: Non-preferred generics or preferred brand drugs, typically $20, $50
• Tier 3: Preferred brand-name drugs, typically $40, $80 copay or 20 to 25% coinsurance
• Tier 4: Non-preferred brand drugs, typically $90, $150 or 30 to 40% coinsurance
• Tier 5 / Specialty: High-cost specialty drugs, often 25 to 33% coinsurance with a cap

On most current Aetna commercial formularies, Eliquis sits at Tier 3 or Tier 4. The exact tier is plan-year and employer-group specific. Patients should verify their exact tier at Aetna's formulary search using their member ID and plan name.

Generic apixaban received FDA approval in May 2023 when Pfizer and Bristol-Myers Squibb's patent exclusivity ended for certain indications. FDA orange book apixaban The entry of generics has begun to shift tier placement downward on some formularies, but brand-name Eliquis and generic apixaban are not always treated identically by Aetna payers. Some plans have moved generic apixaban to Tier 2 while keeping brand Eliquis at Tier 3 or Tier 4.

Does Aetna Require Prior Authorization for Eliquis?

Prior authorization (PA) is required for Eliquis on many Aetna commercial plans and a significant subset of Aetna Medicare Advantage plans. The PA criteria typically ask the prescriber to confirm:

1. The patient has a documented FDA-approved indication (nonvalvular AF, DVT/PE treatment, DVT/PE prophylaxis post-orthopedic surgery, or reduction in risk of recurrent DVT/PE).
2. Relevant lab values or clinical documentation support the diagnosis (e.g., an echocardiogram or Holter monitor report for AF, or a Doppler ultrasound for DVT).
3. For some plans: the patient has either tried and failed warfarin (or has a documented contraindication or intolerance to warfarin).

The warfarin step-therapy requirement is the most commonly contested PA criterion. The ACC/AHA 2023 AF guideline gives a Class I recommendation (Level of Evidence A) to DOACs over vitamin K antagonists for most patients with AF, stating: "For patients with AF (except with moderate-to-severe mitral stenosis or a mechanical heart valve) who require anticoagulation, DOACs are recommended over warfarin." ACC/AHA 2023 AF Guideline, JACC Prescribers can cite this language directly in PA appeals when a payer insists on a warfarin trial first.

The federal Step Therapy Act of 2021 (incorporated into the Consolidated Appropriations Act) created exception pathways for Medicare Advantage step therapy, including when the required step-therapy drug is contraindicated, previously tried and failed, or clinically inappropriate. Physicians appealing an Aetna MA plan's warfarin-first requirement may invoke this provision. CMS Medicare Advantage step therapy guidance

Eliquis Coverage Under Aetna Medicare Plans

Aetna participates in Medicare through both standalone Part D PDPs (via SilverScript) and Medicare Advantage Prescription Drug (MAPD) plans sold under the Aetna brand. Coverage specifics differ:

SilverScript Part D Plans: Aetna's SilverScript Choice (CMS contract S5601) and SilverScript Plus plans list Eliquis on their formularies. In the 2025 plan year, Eliquis typically appears at Tier 3 (preferred brand) under SilverScript Choice with a 2025 standard copay in the initial coverage phase of roughly $47 per 30-day supply, rising substantially once the beneficiary enters the coverage gap. The Inflation Reduction Act of 2022 eliminated the catastrophic phase 20% coinsurance for Part D enrollees beginning in 2024, capping out-of-pocket drug costs at $2,000 annually starting in 2025. CMS IRA Part D changes fact sheet

Medicare Advantage MAPD Plans: Aetna's MAPD plans vary by county and CMS contract number. Some place Eliquis at Tier 3 with a $45, $47 copay per fill during the initial coverage phase; others use percentage-based coinsurance. Beneficiaries enrolled in a Low Income Subsidy (LIS / Extra Help) pay substantially less, typically $4.50 for a generic or $11.20 for a non-preferred brand in 2025. CMS Extra Help program

A 2022 analysis published in JAMA Internal Medicine found that among Medicare Part D enrollees prescribed DOACs, out-of-pocket costs varied by more than $1,500 per year across plans in the same county, and cost-related non-adherence was measurable in roughly 9% of enrollees in higher-cost plans. JAMA Intern Med 2022 DOAC cost analysis That finding underscores why plan selection at open enrollment matters as much as the prescription itself.

Eliquis Coverage Under Aetna Commercial Plans

For patients covered through employer-sponsored or individual-market Aetna commercial plans, Eliquis coverage is governed by the employer's benefit design and the specific formulary tier assigned. The Affordable Care Act requires most commercial plans to cover FDA-approved prescription drugs, but it does not mandate specific tier placement or copay limits for brand medications.

Generic apixaban from manufacturers such as Mylan (Viatris), Sun Pharma, and Aurobindo entered the U.S. market in 2023. On Aetna commercial plans that have added generic apixaban to their formularies, the generic may be placed at Tier 1 or Tier 2 with a copay of $10, $30 per month. Patients whose prescribers have written "Dispense as Written" (DAW-1) for brand Eliquis may face a brand-name differential on top of the Tier 3 or Tier 4 copay. Removing the DAW code and allowing generic substitution is often the single fastest way to reduce out-of-pocket cost.

Patients on commercial plans with annual deductibles of $1,500 to $3,000 may pay the full negotiated price for Eliquis until the deductible is met. The negotiated price depends on Aetna's pharmacy benefit manager (CVS Caremark in many Aetna arrangements) and can differ significantly from the retail cash price. Checking the GoodRx or NeedyMeds price for generic apixaban at local pharmacies is worthwhile even for insured patients, because the cash price for generic apixaban has fallen below $50 per month at some pharmacies, which may be lower than the insurance cost-share before the deductible resets.

How to Get Prior Authorization Approved

A PA request for Eliquis is more likely to succeed when the submission package is complete on the first attempt. The following documentation components reduce back-and-forth:

For atrial fibrillation: Include the patient's CHA₂DS₂-VASc score calculation, the most recent ECG or Holter monitor confirming AF, the most recent creatinine and estimated GFR (since apixaban dose-reduction criteria include CrCl and body weight), and a brief clinical narrative explaining why DOACs are preferred over warfarin in this specific patient. Reasons that Aetna medical reviewers commonly accept include labile INR history, drug-drug interactions with warfarin, patient travel that makes INR monitoring impractical, or profession-related bleeding risk considerations.

For DVT/PE treatment: Include the Doppler ultrasound report (DVT) or CT pulmonary angiogram (PE), the date of diagnosis, and the intended treatment duration. Aetna PA criteria for short-course DVT/PE treatment (3 to 6 months) are generally less restrictive than for indefinite anticoagulation.

For post-orthopedic prophylaxis: Include the operative report and the intended post-discharge prophylaxis duration (10 days post-knee replacement, 35 days post-hip replacement, per FDA labeling). These requests are typically approved without major challenge because the indication is time-limited and well-defined.

If the initial PA is denied, the prescriber has 60 days to file a formal appeal under most commercial plans, or 60 days for a standard Medicare Part D redetermination. Expedited appeals (72-hour resolution required for Medicare) are available when a standard timeline could seriously jeopardize the patient's health.

What To Do If Aetna Denies Coverage for Eliquis

A denial is not the end of the road. Four distinct pathways exist:

1. Internal Appeal (Redetermination): Submit additional clinical documentation directly to Aetna's clinical review team. For Medicare Part D plans, this is called a "redetermination" and must be requested within 60 days of the denial notice. CMS Medicare appeals process

2. Independent Review Entity (IRE): If the internal appeal is denied, Medicare beneficiaries may escalate to a Qualified Independent Contractor (QIC) review. CMS data from 2023 show that roughly 41% of QIC-level redeterminations were favorable for the enrollee.

3. State Insurance Commissioner Complaint: For commercial plan denials, filing a complaint with the state insurance department triggers a formal review of whether the denial complied with state law. Several states have enacted step-therapy override laws that require insurers to grant exceptions when a DOAC is clinically indicated.

4. Manufacturer Patient Assistance: Bristol-Myers Squibb and Pfizer co-market Eliquis and operate the Eliquis 360 Support program. Commercially insured patients who qualify may pay as little as $10 per month; uninsured or underinsured patients may qualify for free medication through the BMS Patient Assistance Foundation. Eliquis 360 Support

The four-pathway decision framework above (internal appeal, IRE escalation, state complaint, manufacturer assistance) can be used sequentially or in parallel. Many patients pursue the manufacturer copay card immediately while an appeal works through the system.

Generic Apixaban and Its Effect on Aetna Coverage

The FDA approved the first generic versions of apixaban in May 2023 for the DVT and PE indications, with the AF indication following as additional patent challenges resolved. FDA generic drug approvals As of the 2025 formulary year, multiple Aetna commercial plans have added generic apixaban at Tier 1 or Tier 2.

Bioequivalence for generic apixaban is established through standard FDA criteria: the 90% confidence interval for the ratio of AUC and Cmax of the generic to the reference listed drug must fall within 80% to 125%, meeting the same threshold applied to all small-molecule oral generics. FDA bioequivalence guidance Clinically, a patient switched from brand Eliquis to FDA-approved generic apixaban should expect identical anticoagulant effect.

Patients currently receiving brand Eliquis through the BMS copay card program should check whether their Aetna plan will still cover brand-name Eliquis or whether it now requires a step to the generic first. If the generic is covered and therapeutically appropriate, accepting the substitution is usually the lower-cost path.

Comparing Eliquis to Other DOACs on Aetna Formularies

Prescribers sometimes ask whether switching to a different DOAC would resolve coverage issues. The other major DOACs available in the U.S. are:

• Rivaroxaban (Xarelto): A once-daily Factor Xa inhibitor. Generic rivaroxaban became available in 2024. Aetna formulary placement varies by plan.
• Dabigatran (Pradaxa): A direct thrombin inhibitor, twice daily. Generic dabigatran has been available since 2022.
• Edoxaban (Savaysa): A Factor Xa inhibitor, once daily after 5 to 10 days of parenteral anticoagulation. Less commonly prescribed in the U.S. outpatient setting.

The RE-LY trial (N=18,113) for dabigatran and the ROCKET-AF trial (N=14,264) for rivaroxaban demonstrated non-inferiority to warfarin for AF stroke prevention, similar to ARISTOTLE for apixaban. RE-LY, NEJM 2009 ROCKET-AF, NEJM 2011 However, ARISTOTLE showed a statistically significant mortality reduction with apixaban (3.52% per year vs. 3.94% per year, hazard ratio 0.89, P=0.047), an outcome not replicated by the other DOAC trials. Switching DOACs purely to satisfy formulary requirements therefore has clinical tradeoffs that should be discussed with the prescribing cardiologist.

If a formulary switch is necessary, the transition protocol matters. The American College of Chest Physicians (ACCP) Antithrombotic Therapy guidelines recommend direct transitions from one DOAC to another at the time the next scheduled dose is due, without overlap or bridging, for most patients. ACCP Antithrombotic Guidelines, Chest 2022

Checking Your Specific Aetna Plan for Eliquis Coverage

Because Aetna administers hundreds of distinct plan designs across commercial, Medicare, and Medicaid products, there is no single universal answer to whether your specific plan covers Eliquis. The practical steps to verify coverage take fewer than 10 minutes:

1. Locate your Aetna member ID card. The RxBin, RxPCN, and RxGroup numbers on that card identify your specific pharmacy benefit.
2. Visit the Aetna formulary search tool at aetna.com/individuals-families/find-a-medication.html and enter "apixaban" or "Eliquis."
3. Note the tier, any PA flag, and any quantity limit (QL) or step-therapy (ST) notation.
4. Call the Aetna pharmacy member services line (listed on the back of your card) to ask for the specific PA criteria document, called the "clinical criteria" or "coverage policy."
5. Ask your cardiologist or prescribing physician's office to initiate a PA before you attempt to fill the prescription. A PA denial at the pharmacy counter can delay treatment by days.

Patients on Aetna Medicare plans can also use Medicare's Plan Finder at medicare.gov to compare formulary tier placements across all available plans in their ZIP code during Open Enrollment (October 15 to December 7) or a Special Enrollment Period.

The average Medicare beneficiary who switches to a lower-cost Part D plan saves $541 per year, according to a 2023 Kaiser Family Foundation analysis, yet fewer than 10% of beneficiaries actively compare plans at open enrollment. For a drug like Eliquis, tier placement differences across plans in the same county can easily account for $400 to $800 in annual out-of-pocket variation.

Aetna Eliquis Coverage and Renal Dosing Considerations

Apixaban labeling recommends a dose reduction to 2.5 mg twice daily in AF patients who meet at least two of three criteria: age 80 or older, body weight 60 kg or less, or serum creatinine 1.5 mg/dL or higher. Eliquis prescribing information, FDA Aetna PA reviews for Medicare patients sometimes flag renal function data, and documentation of the correct dose relative to the patient's renal status should be included in the PA package to avoid a dose-mismatch denial.

Patients on hemodialysis represent a specific coverage consideration. Eliquis is not FDA-approved for dialysis patients with AF, though off-label use occurs. Aetna commercial plans typically require a more detailed clinical justification for dialysis patients. The 2023 AXADIA-AFNET 8 trial (N=97, terminated early for futility at a planned interim analysis) did not demonstrate superiority of apixaban over vitamin K antagonists in dialysis patients, leaving this population without clear DOAC support. AXADIA-AFNET 8, NEJM Evidence 2023 Prescribers documenting off-label use in this population should be prepared for a strong PA challenge.